The concept of innovative drugs has rebounded, with Chimin gaining 6 limit-ups in 12 days, Staidson BioPharm rising over 7%, Hotgen increasing over 5%, and stocks like Medicilon, Cosunter, and BrightGene also seeing gains
The innovative drug concept rebounded, with Chimin hitting 6 trading limits in 12 days, Staidson BioPharm rising over 7%, Hotgen increasing over 5%, and stocks like Medicilon, Cosunter, and BrightGene also seeing gains